Blog

Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy – OncLive


OncLive

Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy
OncLive
The extent of hyperprogressive disease (HPD) after immunotherapy treatment has not been fully characterized, but evidence continues to build that it may not be as rare of a phenomenon as previously thought. Results from a recent multicenter

2018-01-15 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.